KRAS and malignant colon neoplasm: Currently, the pAKT inhibitor MK2206 is in a clinical trial for colon cancers with wild-type KRAS; however, the combination of a HDACi and a pAKT kinase inhibitor was highly effective in inducing apoptosis in the HCT-116 cell line, which is KRAS-mutant, and in re-sensitizing HCT-R cells to the apoptotic effects of HDACis.